Olmesartan
- Generic Name
- Olmesartan
- Brand Names
- Azor, Benicar, Benicar Hct, Olmetec, Olmetec Plus, Tribenzor
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N6O3
- CAS Number
- 144689-24-7
- Unique Ingredient Identifier
- 8W1IQP3U10
- Background
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, valsartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 152
- Registration Number
- NCT00185120
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸Apex Research Institute, Santa Ana, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Olmesartan Medoxomil in Hypertension and Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-10-14
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 393
- Registration Number
- NCT00151827
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 362
- Registration Number
- NCT00151775
Olmesartan Pediatric Pharmacokinetic (PK) Study
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT00151814
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 577
- Registration Number
- NCT00141453
OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study
- Conditions
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2010-10-05
- Lead Sponsor
- OSCAR Study
- Target Recruit Count
- 1000
- Registration Number
- NCT00134160
- Locations
- 🇯🇵
Department of Cardiovascular Medicine Graduate School of Medical Science Kumamoto University, 1-1-1 Honjyo, Kumamoto-City, Kumamoto, Japan
🇯🇵OSCAR-Study Data Center, ShinjukuParkTower30FN, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 84
- Registration Number
- NCT00122447
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Grady Health System, Atlanta, Georgia, United States
Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Atrial Fibrillation Network
- Target Recruit Count
- 422
- Registration Number
- NCT00098137
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.